Matinas BioPharma Holdings, Inc. (MTNB): History, Ownership, Mission, How It Works & Makes Money

Could Matinas BioPharma Holdings, Inc. (MTNB), leveraging its distinctive Lipid Nano-Crystal (LNC) delivery platform aimed at overcoming limitations of traditional therapies, represent a significant opportunity in the biopharmaceutical sector? As a clinical-stage company focused on advancing treatments like MAT2203 for serious fungal infections, MTNB reported financial results indicating a cash runway sufficient to fund operations into 2025, a crucial factor for investors tracking development progress. Are you prepared to explore the historical milestones, ownership intricacies, and the fundamental mechanisms driving MTNB's operational strategy and path towards potential revenue generation?

Matinas BioPharma Holdings, Inc. (MTNB) History

Understanding a company's past is crucial for evaluating its future potential. Let's trace the key steps in Matinas BioPharma's journey.

Matinas BioPharma Holdings, Inc.'s Founding Timeline

Year established

The operating subsidiary, Matinas BioPharma, Inc., was founded in 2010. The current public entity, Matinas BioPharma Holdings, Inc. (MTNB), was formed through a reverse merger transaction completed in 2013.

Original location

The company has consistently operated from New Jersey, with its headquarters currently located in Bedminster.

Founding team members

While specific initial founders are less publicized, key leadership driving the company post-merger includes Jerome D. Jabbour, who has served as CEO, guiding its strategic direction focused on its lipid nano-crystal (LNC) platform technology.

Initial capital/funding

Formation as a public company in 2013 involved financing concurrent with the reverse merger. Early operations were funded through private placements before accessing public markets.

Matinas BioPharma Holdings, Inc.'s Evolution Milestones

Matinas BioPharma Holdings, Inc.'s Transformative Moments

The 2013 reverse merger was pivotal, transforming a private biotech into a publicly traded entity (MTNB), providing necessary access to capital for advancing its drug delivery technology.

Prioritizing the LNC platform and its lead candidate, MAT2203, particularly after halting the MAT2501 program, represented a significant strategic focusing of R&D resources on assets with perceived higher probability of success or market impact.

Actively pursuing and securing LNC platform validation deals with major biopharma companies marked a shift towards leveraging the technology externally, potentially creating non-dilutive funding streams and broader application of the LNC delivery system.

Matinas BioPharma Holdings, Inc. (MTNB) Ownership Structure

Matinas BioPharma Holdings, Inc. operates as a publicly traded entity, meaning its shares are available for purchase by the general public on stock exchanges. This structure results in a dispersed ownership base primarily composed of institutional investors and individual retail shareholders.

Matinas BioPharma Holdings, Inc.'s Current Status

As of the end of 2024, Matinas BioPharma Holdings, Inc. is listed on the NYSE American stock exchange under the ticker symbol MTNB. Its public status subjects it to regulatory oversight by the Securities and Exchange Commission (SEC), requiring regular financial disclosures and adherence to specific governance standards.

Matinas BioPharma Holdings, Inc.'s Ownership Breakdown

Understanding the ownership distribution provides insight into shareholder influence. For a deeper dive into the company's financial standing, consider Breaking Down Matinas BioPharma Holdings, Inc. (MTNB) Financial Health: Key Insights for Investors.

Note: Ownership percentages are approximate based on available data from late 2024 filings and can fluctuate.

Matinas BioPharma Holdings, Inc.'s Leadership

The company's strategic direction and day-to-day operations are guided by its executive management team and Board of Directors. Key leadership figures steer the company's research, development, and commercialization efforts. As of the close of 2024, the primary leadership included:

• Jerome D. Jabbour: Chief Executive Officer and Director
• Keith A. Kucinski: Chief Financial Officer
• Theresa Matkovits, Ph.D.: Chief Development Officer
• Raphael J. Mannino, Ph.D.: Chief Scientific Officer

This team brings extensive experience in biotechnology, drug development, and corporate finance, shaping the company's path forward in addressing infectious diseases and other therapeutic areas.

Matinas BioPharma Holdings, Inc. (MTNB) Mission and Values

Matinas BioPharma centers its purpose on leveraging its unique lipid nano-crystal (LNC) platform technology to develop novel, orally delivered therapies for challenging medical needs. The company's direction reflects a commitment to addressing limitations of existing treatments, particularly concerning toxicity and delivery.

Matinas BioPharma's Core Purpose

While the company does not prominently display a formal, single-sentence mission or vision statement in its recent public materials as of early 2024, its core purpose is consistently communicated through its focus and actions.

Official mission statement

An explicitly stated official mission statement is not readily available on the company's main corporate communication channels. However, their operational focus implies a mission centered on developing and commercializing therapies using their LNC platform to overcome delivery challenges and improve patient outcomes in areas with significant unmet medical needs.

Vision statement

Similar to the mission statement, a distinct vision statement is not formally articulated. The company's vision appears to be becoming a leader in intracellular drug delivery, transforming therapies that currently require intravenous administration into safer, more effective oral options. Understanding who invests in this vision is key; Exploring Matinas BioPharma Holdings, Inc. (MTNB) Investor Profile: Who’s Buying and Why? offers insights.

Company slogan

Matinas BioPharma does not appear to utilize a specific, widely promoted company slogan.

Matinas BioPharma Holdings, Inc. (MTNB) How It Works

Matinas BioPharma functions as a clinical-stage biopharmaceutical company, primarily leveraging its proprietary Lipid Nano-Crystal (LNC) platform technology to develop novel therapies for infectious diseases and other conditions. The company focuses on creating orally administered versions of potent drugs that are typically delivered intravenously, aiming to improve safety, tolerability, and patient convenience.

Matinas BioPharma Holdings, Inc.'s Product/Service Portfolio

Matinas BioPharma Holdings, Inc.'s Operational Framework

The company's operations revolve around research and development, centered on advancing its LNC platform and pipeline candidates through preclinical and clinical trials. Value creation stems from demonstrating the efficacy and safety of its drug candidates to regulators and potential partners. Key operational activities include:

• Conducting clinical trials (like the ongoing Phase 3 trial for MAT2203).
• Managing regulatory submissions and interactions with bodies like the FDA.
• Pursuing strategic partnerships and collaborations to leverage the LNC platform for other therapeutic agents.
• Investing significantly in R&D; for the nine months ended September 30, 2024, R&D expenses were approximately $16.2 million.

Successful clinical data and regulatory milestones are crucial operational outputs driving potential future revenue streams through product approvals or licensing deals. You can explore more details by Breaking Down Matinas BioPharma Holdings, Inc. (MTNB) Financial Health: Key Insights for Investors.

Matinas BioPharma Holdings, Inc.'s Strategic Advantages

Matinas BioPharma's primary competitive edge lies in its proprietary LNC delivery technology. This platform offers a distinct approach to solving drug delivery challenges, potentially opening up oral administration routes for drugs previously limited to IV delivery. This could significantly improve patient compliance and reduce healthcare costs.

Further advantages include:

• Focus on niche indications with high unmet medical needs, such as invasive fungal infections, potentially allowing for orphan drug designations and expedited regulatory pathways.
• The potential broad applicability of the LNC platform beyond infectious diseases to areas like oncology, metabolic diseases, and vaccines creates multiple avenues for future growth and partnerships.
• An experienced management team navigating the complex landscape of drug development and clinical trials.

Matinas BioPharma Holdings, Inc. (MTNB) How It Makes Money

As a clinical-stage biopharmaceutical company, Matinas BioPharma currently generates revenue primarily through strategic research and development collaborations and licensing agreements related to its LNC platform technology, rather than direct product sales.

Matinas BioPharma Holdings, Inc.'s Revenue Breakdown

Revenue streams reflect its focus on advancing its technology platform and clinical candidates through partnerships. Based on reporting through the third quarter of 2024, the sources are concentrated.

Matinas BioPharma Holdings, Inc.'s Business Economics

The company's economic model is characteristic of a development-stage biotech firm. Its success hinges on the successful clinical advancement and eventual regulatory approval and commercialization of drug candidates derived from its lipid nanocrystal (LNC) delivery technology.

• Significant investment in research and development (R&D) is the primary cost driver, fueling pipeline progression.
• Clinical trial expenses for candidates like MAT2203 represent substantial operational costs.
• Future value is heavily tied to achieving clinical milestones, securing regulatory approvals, and either commercializing products independently or through lucrative licensing deals.
• The company relies on equity financing and collaborations to fund operations until product revenue streams are established. Understanding the investor base is key; Exploring Matinas BioPharma Holdings, Inc. (MTNB) Investor Profile: Who’s Buying and Why? offers insights.

Profitability is contingent upon future events, specifically the market adoption of its LNC-based therapies or further partnerships.

Matinas BioPharma Holdings, Inc.'s Financial Performance

Financial results leading into the end of 2024 reflect its clinical-stage status. For the nine months ending September 30, 2024, the company reported collaboration revenue of approximately $1.9 million. However, high operating costs led to a net loss. Key metrics illustrate this phase:

• Research and Development (R&D) expenses were approximately $12.8 million for the first nine months of 2024, underscoring the focus on pipeline development.
• General and Administrative (G&A) expenses were around $7.5 million for the same period.
• The Net Loss attributable to common stockholders for the nine months ended September 30, 2024, was approximately $18.1 million.
• The company maintained a cash and cash equivalents balance of roughly $14.5 million as of September 30, 2024, highlighting the importance of cash management and funding runway.

These figures demonstrate the typical financial profile of a biotech investing heavily in future potential rather than current profitability.

Matinas BioPharma Holdings, Inc. (MTNB) Market Position & Future Outlook

Matinas BioPharma is carving out a niche in the biopharmaceutical sector with its proprietary Lipid Nano-Crystal (LNC) platform delivery technology, aiming to enhance existing therapies. Its future outlook hinges significantly on the clinical success and regulatory approval of its lead candidates, particularly MAT2203 for invasive fungal infections.

Competitive Landscape

The company operates in a competitive field, facing established treatments and other novel delivery platforms.

Opportunities & Challenges

Navigating the path to commercialization involves balancing significant potential with inherent risks.

Industry Position

As a clinical-stage company, Matinas BioPharma is positioned as an innovator focused on drug delivery solutions rather than novel compound discovery. Its value proposition lies in reformulating known drugs to create potentially safer and more effective oral versions. Success depends heavily on demonstrating clinical superiority or advantages over existing standards of care, particularly intravenous formulations like Amphotericin B. The company's standing relies on continued progress through clinical trials and navigating the complex regulatory landscape. A deeper dive into its financial footing is crucial for assessing its runway and ability to execute its strategy; you can explore Breaking Down Matinas BioPharma Holdings, Inc. (MTNB) Financial Health: Key Insights for Investors for more details. Its LNC platform represents its core asset, differentiating it within the specialized field of drug delivery technology companies.